QuidelOrtho has signed a long-term agreement with Lifotronic Technology to expand its range of immunoassay instruments worldwide. This partnership will help QuidelOrtho offer more affordable and high-quality solutions in markets outside the U.S.
The deal gives QuidelOrtho access to several new immunoassay platforms that can handle both high and low-volume testing. The partnership will add over 25 new tests to their current range, expanding their total offering to over 70 tests on these new platforms.
These new tests will allow QuidelOrtho to compete better in global markets and serve different lab needs, from smaller labs to large facilities that require more testing capacity.
The focus will be on regions including Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and the Asia-Pacific. This expansion will help QuidelOrtho close any gaps in their offerings and strengthen their position in international markets.
Executive Statement
According to Bryan Hanson, Senior Vice President of Global Clinical Laboratory and Transfusion Medicine at QuidelOrtho, through their collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance their long-term innovation strategy in core growth markets. This agreement strengthens their portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions.
